Doctors use three pieces of information to decide when a prostate biopsy is needed to confirm a diagnosis of prostate cancer:
PSA is a protein produced by the prostate. Because men with cancerous prostates tend to have higher blood PSA levels than men with healthy prostates, the test is widely used to screen for early prostate cancer. But since all prostate cells, noncancerous (benign) and cancerous (malignant), produce PSA, the test produces many false-positive and false-negative results.
When a biopsy is needed, most often the recommended procedure is a transrectal core biopsy.
Ways To Detect Prostate Cancer
To evaluate prostate cancer, doctors consider three factors:
Prostate cancer usually begins in one area of the gland and then spreads. It usually first spreads within the prostate, often very slowly. Those cancers that are destined to grow more quickly will next move toward the outside surface of the prostate (called the capsule). Next, it may spread further -- to the seminal vesicles and neighboring tissues. Finally, the prostate cancer may reach the lymph nodes and bones. The disease requires different treatment based on its location.
In addition to the use of PSA as a screening test, PSA also provides guidance to help determine the need for additional testing. For most men with PSAs below 10 nanograms per milliliter (ng/mL), the results of bone scans, computed tomographic (CT) scanning, and magnetic resonance imaging (MRI) are rarely positive. Even though these imaging tests are not necessary, many doctors order them. Many other doctors say its a waste of money. And for the man, the results can produce as much worry as reassurance.
On the other hand, men should have imaging tests if they have the following:
In such cases, MRI or CT scanning can look for enlarged lymph nodes in the pelvis and abdomen. A bone scan can look if the disease has spread (metastasized). A nuclear imaging test called the ProstaScint appears less useful than standard imaging techniques.
Unfortunately, men with negative scans may still have the microscopic spread of the tumor through the surface (capsule) of the prostate gland. Knowing this is crucial. It determines if a man is a candidate for surgery. The only way to be sure if the cancer has spread or not is to remove the gland surgically. It is then sent to a pathologist for evaluation.
The major anatomic system for evaluating prostate cancer is called the TNM system. It is based on the size of the tumor and whether it has remained confined to one place or spread to lymph nodes and/or distant sites.
T represents the size and amount of local spread of the primary tumor. Very small cancers are called T1. Stages T3 and T4 are large cancers that have extended beyond the outer capsule of the prostate.
N represents the number and extent of spread to lymph nodes. N0 indicates no lymph node involvement. N1 through N4 correlate with the extent of the spread to the lymph nodes.
M is an indication of whether the cancer has spread to distant places (called metastases), such as the bones or lungs. M0 means no metastases. M1 means the cancer has spread to distant places.
Anatomic staging is crucial to planning treatment. The prognosis for men with prostate tumors confined to the prostate gland (stages T1 and T2) is better than in men with more advanced cancers. Men with early, organ-confined disease also have the option of surgery as a potential cure. Men with more extensive disease cannot be cured by surgery alone. They will usually need hormonal therapy, perhaps combined with radiation therapy.
A prostate biopsy establishes the diagnosis of cancer. The biopsy also provides valuable information.
When a urologist performs a transrectal biopsy, at least 6 -- and often 12 to 20 -- tissue specimens are obtained. Pathologists examine each specimen (they call them cores). The fewer cores that have cancer cells, the better the outlook. In general, when at least two cores are positive and one of them contains at least 50% cancer cells, there is an increased risk that the tumor has spread to the outer surface of the gland (the capsule) and beyond.
Pathologists diagnose cancer by examining biopsy specimens under a microscope. But they also evaluate how malignant the cells look:
In general, specimens with well-differentiated cancers have the best prognosis and poorly differentiated ones have the worst.
Prostate cancers also are classified using the Gleason grading system. The Gleason system combines two features of how prostate cancer appears under the microscope and grades each from 1 to 5 (5 is the worst):
Each feature is given a score. The lowest possible score is 2, which indicates a cancer that would likely be very slow growing and not need any treatment. The highest score is 10. This indicates a very aggressive cancer with a poor prognosis if not treated.
Scientists are working hard to develop better systems, but until they succeed, the Gleason score will remain the best guide to a tumors likely behavior.
Anatomic staging and microscopic grading are valuable ways to predict how prostate cancer will behave, but they are imperfect. New approaches focus on biologic markers.
The best biologic marker to predict how a mans prostate cancer will behave is the prostate specific antigen (PSA). In general, here is what we know about PSA levels and prostate cancer:
The rate at which PSA levels rise over time is called the PSA velocity. A PSA rise of more than 2 ng/mL in the year before a cancer was diagnosed suggests a relatively high risk of death from prostate cancer.
Newer biologic markers are being studied. The most promising rely on identifying the genetic abnormalities that fuel the growth of malignant cells. These tests are still experimental.